Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0BGJNX
ADC Name	TAK-500
Synonyms	TAK500; TAK 500 Click to Show/Hide
Organization	Takeda Pharmaceutical Co., Ltd.
Drug Status	Phase 1
Indication	In total 7 Indication(s) Gastroesophageal cancer [ICD11:2B71] Phase 1 Head and neck squamous carcinoma [ICD11:2C31] Phase 1 Hepatocellular carcinoma [ICD11:2C12] Phase 1 Non-small cell lung cancer [ICD11:2C25] Phase 1 Pancreatic cancer [ICD11:2C10] Phase 1 Pleural mesothelioma [ICD11:2C26] Phase 1 Triple negative breast cancer [ICD11:2C60-2C65] Phase 1
	3D MOL	2D MOL
Antibody Name	Anti-CCR2 TAK500 IgG1 mAb		Antibody Info
Antigen Name	C-C chemokine receptor type 2 (CCR2)		Antigen Info
Payload Name	STING agonist		Payload Info
Therapeutic Target	Stimulator of interferon genes protein (STING1)		Target Info
Linker Name	Maleimido-caproyl		Linker Info

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT04879849	Phase 1	An open-label, phase 1, dose-escalation study to evaluate the safety and preliminary antitumor activity of TAK-676 with pembrolizumab following radiation therapy in the treatment of non-small-cell lung cancer, triple-negative breast cancer, or squamous-cell carcinoma of the head and neck that has progressed on checkpoint inhibitors. Click to Show/Hide
Undisclosed	NCT04420884	Phase 1	An open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-676 as a single agent and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT04879849	Clinical Status	Phase 1
Clinical Description	An open-label, phase 1, dose-escalation study to evaluate the safety and preliminary antitumor activity of TAK-676 with pembrolizumab following radiation therapy in the treatment of non-small-cell lung cancer, triple-negative breast cancer, or squamous-cell carcinoma of the head and neck that has progressed on checkpoint inhibitors.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT04420884	Clinical Status	Phase 1
Clinical Description	An open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-676 as a single agent and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.

References

Ref 1	An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
Ref 2	An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors